MBRX - Moleculin Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.7400
+0.1500 (+9.43%)
At close: 4:00PM EDT

1.6300 -0.11 (-6.32%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close1.5900
Open1.6400
Bid1.6000 x 1000
Ask1.6300 x 1200
Day's Range1.6000 - 2.1200
52 Week Range0.7772 - 3.1500
Volume34,545,663
Avg. Volume2,459,151
Market Cap59.828M
Beta (3Y Monthly)1.76
PE Ratio (TTM)N/A
EPS (TTM)-0.4580
Earnings DateApr 3, 2019 - Apr 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    Moleculin Announces $15.0 Million Registered Direct Offering

    HOUSTON, April 23, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of 9,375,000 units at a public offering price of $1.60 per unit in a registered direct offering. The offering is expected to close on or about April 25, 2019, subject to customary closing conditions. The gross proceeds of the offering are expected to be approximately $15.0 million, prior to deducting the placement agent fees and other estimated offering expenses.

  • Benzinga2 days ago

    The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) Moleculin Biotech Inc (NASDAQ: MBRX ) (announcement ...

  • PR Newswire3 days ago

    Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019

    HOUSTON , April 22, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug ...

  • PR Newswire7 days ago

    Moleculin Receives FDA Approval of Fast Track Designation for Annamycin

    HOUSTON, April 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the U.S. Food and Drug Administration ("FDA") has approved its request for Fast Track Designation for its drug, Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia ("AML").

  • PR Newswire8 days ago

    Moleculin Announces Significant Discovery in Lung Cancer Models

    "We know that Annamycin was previously shown to be significantly more potent than doxorubicin in both Lewis lung carcinoma in vivo and small cell lung cancer in vitro models," commented Walter Klemp, Moleculin's Chairman and CEO. "Now we are seeing significant activity against triple negative breast cancer that has metastasized to the lungs.

  • PR Newswire14 days ago

    Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial

    HOUSTON, April 11, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has entered into an agreement with Emory University to conduct a Phase 1 clinical trial of WP1066 in children with recurrent or refractory malignant brain tumors. "Given the exciting data Emory University researchers presented at the recent Society for Neuro Oncology conference, we have been working closely with them to begin a trial in pediatric brain tumors," commented Walter Klemp, Moleculin's Chairman and CEO. This will also give us yet another opportunity to develop human proof of concept data, bringing our total number of clinical trials to five.

  • PR Newswire16 days ago

    Moleculin Announces Successful Expansion of its Leukemia Drug Program

    HOUSTON, April 9, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has successfully expanded the clinical supply of Annamycin for its on-going clinical trials via BSP Pharmaceuticals S.p.A. (www.bsppharmaceuticals.com) in Latina, Italy. "Securing production supply for a liposomal anthracycline like Annamycin is no trivial matter, which is why we partnered last year with a quality supplier like BSP, who will be able to supply Annamycin in commercial quantities going forward," commented Walter Klemp, Moleculin's Chairman and CEO.

  • PR Newswire22 days ago

    Moleculin Announces Preclinical Pancreatic Cancer Data Presented at American Association for Cancer Research Annual Meeting

    The presentation included data resulting from preclinical evaluation in pancreatic cancer models of STAT3 inhibitors WP1066 and WP1732, both discovered at The University of Texas MD Anderson Cancer Center and licensed by Moleculin. WP1066 is an orally bioavailable drug with significant brain uptake that is currently in Phase I clinical studies in patients with brain tumors.

  • PR Newswire24 days ago

    EnerCube Completes Complex Design Project With Altasteel

    TORONTO, April 1, 2019 /PRNewswire/ -- CellCube Energy Storage Systems Inc. ("CellCube" or the "Company") (CSE CUBE) (CUBE.CN) (CECBF) (Frankfurt 01X, WKN A2JMGP) on behalf of its wholly-owned subsidiary, EnerCube Switchgear Systems Inc. ("EnerCube") is pleased to announce EnerCube has completed a significant sale and complex switchgear upgrade to the AltaSteel plant. AltaSteel is a Canadian manufacturer of prime quality steel products for the mining, construction, automotive and engineering industries based in Edmonton, Alberta.

  • PR Newswire29 days ago

    Moleculin Announces Pricing Of Underwritten Public Offering

    HOUSTON, March 27, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the pricing of an underwritten public offering of an aggregate of 5,250,000 units at a public offering price of $1.00 per unit. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock for a total of 5,250,000 shares of common stock and warrants to purchase 2,625,000 shares of common stock.

  • PR Newswire29 days ago

    Moleculin Announces Proposed Underwritten Public Offering

    The Company intends to use the net proceeds of the offering to fund its planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes. The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-219434) previously filed with and declared effective by the Securities and Exchange Commission (SEC).  A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov.

  • PR Newswirelast month

    Moleculin Announces Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in the US and in Poland

    HOUSTON, March 26, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced positive interim safety and efficacy data from two ongoing open label, single arm Phase 1/2 studies of Annamycin.  In the first study, being conducted in the US, four patients have completed treatment at 100 mg/m2 with no significant adverse events related to Annamycin, and the study will now proceed to the next higher dose of 120 mg/m2. The second trial, taking place in Poland, started at a 120 mg/m2 dose of Annamycin and has treated three patients.

  • PR Newswirelast month

    Moleculin Announces First Patients Enrolled in Lymphoma Clinical Trial

    HOUSTON, March 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the first two patients have been enrolled in its European clinical trial of WP1220 for the topical treatment of cutaneous T-cell lymphoma (CTCL). "This now marks four clinical trials with patients enrolled," commented Walter Klemp, Moleculin's Chairman and CEO. "In this case, we are targeting CTCL with a topical p-STAT3 inhibitor in light of the significant role that STAT3 appears to play in CTCL skin lesions.

  • PR Newswirelast month

    Moleculin Announces Memorial Sloan Kettering Chief of Leukemia Joins Science Advisory Board

    HOUSTON , March 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug ...

  • PR Newswirelast month

    Moleculin Biotech, Inc. to Present at the Oppenheimer 29th Annual Healthcare Conference and the 31st Annual ROTH Conference

    Management will present on Wednesday, March 20, 2019 at 3:20 p.m. ET. The Conference will be held at the Westin New York Grand Central Hotel in New York City. 31st Annual ROTH Conference – Management will be available on Monday, March 18, 2019 for one-on-one meetings with investors.

  • ACCESSWIRElast month

    Moleculin Announces First Patients Treated in European Annamycin Clinical Trial

    HOUSTON, TX / ACCESSWIRE / March 14, 2019 / Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the first patients have been treated in the Company's second clinical trial to study Annamycin for the treatment of relapsed and refractory adults with acute myeloid leukemia. The Company further reported that the initial treatment of the first patient appeared to be well tolerated.

  • ACCESSWIRElast month

    Moleculin Files with FDA for Expedited Approval Pathway for Annamycin

    HOUSTON, TX / ACCESSWIRE / March 13, 2019 / Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has submitted a request for Fast Track Designation with the US Food and Drug Administration (FDA) for its drug, Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia (AML). "Now that we have some traction in our clinical trials of Annamycin for the treatment of relapsed or refractory AML," commented Walter Klemp, Moleculin's Chairman and CEO, "we believe it is appropriate to request Fast Track designation for Annamycin.

  • Benzinga2 months ago

    The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 21.) Eli Lilly And Co (NYSE: LLY ) Gossamer ...

  • GlobeNewswire2 months ago

    Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2018

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced its financial results for the year ended December 31, 2018. Additionally, the Company announced potential upcoming milestones and recent corporate developments. The recent initiation of our WP1220 skin cancer clinical trial in Poland achieves an important milestone - Moleculin now has three unique drug candidates in four ongoing clinical trials.

  • GlobeNewswire2 months ago

    Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has entered into a sublicense agreement with WPD Pharmaceuticals (WPD), located in Poland. The agreement provides WPD with exclusive rights, subject to current license agreements, to develop and market a range of Moleculin’s technologies in certain European countries (which does not include the UK, France, Italy and Spain) in exchange for contributing a minimum of $4 million in development expenditures agreed upon by Moleculin during the term of the agreement plus an ongoing royalty on future revenues.

  • PR Newswire2 months ago

    Northern Lights Supply Store in Alberta Receives First Inventory in Preparation for Grand Opening

    VANCOUVER, British Columbia, Feb. 19, 2019 /PRNewswire/ -- Weekend Unlimited Inc. ("Weekend" or the "Company") (CSE:POT) (0OS1.SG)  (WKULF) is pleased to announce that Northern Lights Supply in Nisku, Alberta has received its initial shipment from AGLC allowing it to set a grand opening date for February 23rd. "Having received the store's initial order, we are currently stocking the shelves and conducting our final staff training and systems checks in order to hold our grand opening next week, on February 23rd," said Northern Lights Supply President, Derek Shields.

  • PR Newswire2 months ago

    Premier Health Provides Corporate Update

    VANCOUVER, British Columbia, Feb. 14, 2019 /PRNewswire/ -- Premier Health Group (CSE:PHGI) (PHGRF) (Frankfurt: 6PH) (the "Company" or "Premier Health"), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to provide a corporate update.

  • GlobeNewswire3 months ago

    Moleculin Announces Approval for Third Drug to Commence Clinical Trials

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has received approval to begin clinical trials in Poland for its STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (“CTCL”). “This marks an important milestone for Moleculin.

  • ACCESSWIRE3 months ago

    4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19)

    CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The healthcare stock market has been a hotbed of excitement over the course of the past couple of years as companies across the healthcare industry have employed more nuanced approaches to how they offer care to patients. With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Moleculin Biotech Inc (MBRX), Celldex Therapeutics Inc (CLDX), and Teladoc Health Inc (TDOC) represent four healthcare companies focused on innovating towards the future of healthcare.

  • GlobeNewswire3 months ago

    Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate WP1066 for the treatment of glioblastoma, the most aggressive form of brain tumor.